The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin

Robert Raschke, MD, MS; Jack Hirsh, MD, FCCP; and James R. Guidry, PharmD
[+] Article, Author, and Disclosure Information

From Good Samaritan Regional Medical Center, Phoenix, Arizona; Henderson Civic Hospital Research Center, Hamilton, Ontario, Canada; and Desert Samaritan Medical Center, Mesa, Arizona.

Potential Financial Conflicts of Interest:Honoraria: R. Raschke (Aventis).

Requests for Single Reprints: Robert Raschke, MD, MS, Good Samaritan Regional Medical Center, 1111 East McDowell Road, Phoenix, AZ 85006; e-mail, robertraschke@bannerhealth.com.

Current Author Addresses: Dr. Raschke: Good Samaritan Regional Medical Center, 1111 East McDowell Road, Phoenix, AZ 85006.

Dr. Hirsh: Henderson Civic Hospital Research Center, 711 Concession Street, Hamilton, Ontario L8V 1C3, Canada.

Mr. Guidry: Clinical Pharmacy, Desert Samaritan Medical Center, 1400 South Dobson Road, Mesa, AZ 85202.

Author Contributions: Conception and design: R. Raschke, J. Hirsh, J.R. Guidry.

Analysis and interpretation of the data: R. Raschke, J. Hirsh, J.R. Guidry.

Drafting of the article: R. Raschke, J.R. Guidry.

Critical revision of the article for important intellectual content: R. Raschke, J. Hirsh, J.R. Guidry.

Final approval of the article: R. Raschke, J. Hirsh, J.R. Guidry.

Provision of study materials or patients: R. Raschke, J.R. Guidry.

Statistical expertise: R. Raschke.

Administrative, technical, or logistic support: R. Raschke, J.R. Guidry.

Collection and assembly of data: R. Raschke, J.R. Guidry.

Ann Intern Med. 2003;138(9):720-723. doi:10.7326/0003-4819-138-9-200305060-00008
Text Size: A A A

Background: Site-specific validation of the activated partial thromboplastin time (aPTT) therapeutic range is required to ensure administration of the optimal dose of unfractionated heparin. Therapeutic ranges of 1.5 to 2.5 times the control value are subtherapeutic for most modern aPTT reagents.

Purpose: To audit the appropriateness of aPTT monitoring in clinical trials comparing unfractionated heparin and low-molecular-weight heparin in patients with venous thromboembolism.

Data Sources: Search of PubMed database from 1984 to 2001.

Study Selection: Randomized, controlled trials that compared unfractionated and low-molecular-weight heparin for the treatment of venous thromboembolism.

Data Extraction: Use of unvalidated and potentially suboptimal therapeutic ranges for aPTT in patients assigned to receive unfractionated heparin.

Data Synthesis: Fifteen studies met inclusion criteria. Only 3 studies used a validated aPTT therapeutic range, and 11 studies used a range that included aPTT values 1.5 times the control value. Ten studies reported unfractionated heparin doses, and 7 of these documented a reduction to less than 30 000 U/d in response to aPTT results.

Conclusions: Most studies monitored unfractionated heparin inappropriately. This shortcoming could be responsible for the reduced efficacy of unfractionated heparin in clinical trials.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

What Is the Most Effective Blood Thinner for Treating Patients with Blood Clots in the Veins?

The summary below is from the full report titled “Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin.” It is in the 6 May 2003 issue of Annals of Internal Medicine (volume 138, pages 720-723). The authors are R. Raschke, J. Hirsh, and J.R. Guidry.


Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.